List view / Grid view
How will a new regulatory landscape impact the EU and UK pharma industries? Early 2022 will see major new clinical trial legislation come into effect, with proposals for an entirely new regulatory regime promised by the end of the year. Paul Ranson, Consultant at Morgan Lewis, reflects on this and…
Here, Dave Elder reflects on the pharma industry’s efforts to get greener; highlighting the confounding issues that mean it is not always easy to achieve.
Following his first full year as Managing Director UK, Ireland & Nordics for Novartis Pharmaceuticals, healthcare leader Chinmay Bhatt shares his learnings from the pandemic and reflects on what’s next.
John Liddell, Chief Technologist at the Centre for Process Innovation (CPI), writes about the challenges associated with gene therapy products, which constitute a major portion of the overall cell and gene therapy market.
In the quest for fast and reliable ingredient analysis, Christian W Huck, Krzysztof B Bec and Justyna Grabska from the Institute of Analytical Chemistry and Radiochemistry at the University of Innsbruck, consider the use of portable NIR spectroscopy, comparing the results from standard and miniaturised sensors.
Richard Crocombe of Crocombe Spectroscopic Consulting surveys the use of portable spectrometers in pharmaceutical manufacturing, with an emphasis on vibrational spectroscopy. Ideal and typical features of portable spectrometers are reviewed, alongside explanation of why device characteristics and sample presentation are critical to obtaining meaningful results.
Most intracellular drug targets remain intractable due to cellular membranes effectively denying large foreign molecules entry into the cytoplasm. Over recent decades, several technologies that enable biologics to enter cells have emerged, but successes remain limited to date. Here, Sapreme Technologies’ Miriam Bujny, Chief Development Officer, and Guy Hermans, Chief…
A significant obstacle still faced in oncology is damage to healthy cells inflicted during treatment, which robs patients of their quality of life while battling cancer. Targeted radionuclide therapy (TRT) is a type of radiomolecular precision oncology that addresses this issue by deploying cancer-killing radiation directly to tumour cells, with…
The brain is protected by the blood-brain barrier, a multi-layered structure which helps to protect it from the invasion of pathogens or unwanted substances and limits drug transport into the brain via the bloodstream. Here, Dr Oliver Ernst and Dr Heiko Manninga from German biotech company NEUWAY Pharma share details of…
The Celsis Adapt™ unlocks advantages of utilising a single in-house RMM, achieving critical results necessary to ensure patient safety.
There are several end-product formats companies can choose from when developing sterile injectable drugs. The most common ones are liquid or lyophilized vials, prefilled syringes, and cartridges. Due to an increase in self-administration of injectable drugs, the market of drug products in prefilled syringes is expected to reach $9.53 billion…
Articles featured in this in-depth focus discuss a technology enabling drugs to be delivered across the blood-brain barrier, the potential of targeted radionuclide therapy as a precision oncology treatment and novel bioconjugation methods to improve biologics drug delivery.
Articles in this in-depth focus explore the applications of portable spectrometers and review their critical features, as well as comparing the results of standard and miniaturised NIR spectroscopy sensors in medicinal plant QC.
In our latest journal, discover the innovations enabling drugs to be delivered across the blood-brain barrier, the challenges associated with downstream purification of cell and gene therapies, as well as applications of NIR spectroscopy in ingredient analysis. Also featured in this issue, explore the development and future potential of radiomolecular…
